TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01636570
Drug: Placebo Comparator: Sugar Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given in identical gelcaps (as microcrystalline cellulose) as 2 per day for a period of 6 months.
Study: NCT00307645
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00245544
Drug: MK0759
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04910230
Drug: nicotinamide
Normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In addition to usual care, the treatment group was given 500mg nicotinamide daily, divided into 5 doses
Study: NCT00307645
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01738542
Drug: Antiaggregant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAS 100mg/d or Clopidogrel 75mg/d
Study: NCT03252938
Drug: IMP321
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAG-3Ig fusion protein, highly potent activator of antigen presenting cells
Study: NCT01738542
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01244126
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2mcg/kg fentanyl IN
Study: NCT03596372
Drug: BAY1834942
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation:~Sequential dose levels~.~Dose expansion (except for low-dose expansion):~With maximum tolerated dose (MTD) identified in dose escalation part.
Study: NCT03420014
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2 doxorubicin will be administered once every 3 weeks (Day 1 of every 21-days cycle).
Study: NCT04209855
Drug: Pegylated liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin will be administered per dose and schedule specified in the arm.
Study: NCT01909557
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03453840
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Children will receive the dispersible formulation of AL which contains 20 mg artemether, 120 mg of lumefantrine (Coartem® Dispersible). Weight-based dosing will be as below: \<15kg, 1tablet; 15-25kg, 2 tablets; 25-35kg, 3 tablets; \>=35kg, 4 tablets.
Study: NCT00850590
Drug: NRL001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four single doses of NRL001 or placebo. NRL001 is administered at lower (5, 7.5 and 10 mg) or higher (10, 12.5 and 15 mg) doses in a slow release rectal suppository weighing either 1 g or 2 g.
Study: NCT01451762
Drug: .9 normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: .9 normal saline administered before surgery.
Study: NCT03576599
Drug: Zoledronic Acid Injectable Product
Normalized name: zoledronic acid Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: One Group are randomiced to Zoledronic Acid Injectable Product and one Group to Placebo
Study: NCT03576599
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01491009
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion
Study: NCT01471847
Drug: BEZ235 + Trastuzumab Phase l/Phase ll)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase l: Patients will receive increasing doses of oral BEZ235 (BID) together with standard weekly trastuzumab at a fixed dose. BEZ235 doses will be escalated in cohorts of 3 to 6 patients guided by an adaptive Bayesian logistic regression model with overdose control until MTD/RP2D has been established.~Phase ll: If randomized to the trastuzumab + BEZ235 arm, patients will receive standard weekly trastuzumab in combination with oral BEZ235 (BID) at the MTD or RP2D and will continue on study treatment until PD, unacceptable toxicity or until other pre-defined discontinuation criteria are met. They will have regular safety assessments and will be evaluated for response to treatment according to RECIST every 2 cycles for the first 36 weeks then every 12 weeks until disease progression (or start of new anti-neoplastic therapy).
Study: NCT01471847
Drug: Lapatinib + Capecitabine (Phase II)
Approvals — FDA: no, EMA: no, PMDA: no
Description: If randomized to the lapatinib + capecitabine treatment arm, patients will receive standard lapatinib plus capecitabine until PD, unacceptable toxicity or until other pre-defined discontinuation criteria are met.~Patients will have regular safety assessments and will be evaluated for response to treatment according to RECIST every 2 cycles for the first 36 weeks then every 12 weeks until disease progression (or start of new anti-neoplastic therapy). After progression, survival f-up will continue.~All patients participating in the Phase II part of the study will be required to have available archival or fresh tumor tissue for biomarker analysis prior to treatment start
Study: NCT00245609
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00907998
Drug: APL180
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00907998
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01701024
Drug: ACYC
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACYC active, topically applied to the face for 12 weeks
Study: NCT02019056
Drug: Placebo /bid P.O
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04722120
Drug: Low contrast dose CT
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Underwent liver CT 20% lower dose contrast media.
Study: NCT04722120
Drug: Conventional CT (contrast agent)
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Underwent liver CT without change of contrast media doses.
Study: NCT00863746
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 2 tablets twice daily (BID)
Study: NCT01924858
Drug: GSK2647544 oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2647544 100 mg will be supplied as a size 0 swedish orange hard gelatin capsules filled with white/slightly colored granule. Subjects will receive a single oral dose of GSK2647544 100 mg (2 X 50mg capsules) with 150 mL of tepid water approximately 2 hours prior to the IV infusion of \[18F\]-GSK2647544 and a PET scan.
Study: NCT01924858
Drug: [18F]GSK2647544 IV bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]GSK2647544 will be supplied as a clear, colourless solution free from visible particle. A maximum dose up to 2 mg with a maximum dose volume of 25 mL will be administered as IV bolus over 60 seconds.
Study: NCT03043547
Drug: nal-IRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: nal-IRI \[Irinotecan liposome\] (80 mg/m2 as a 1.5 hour infusion)
Study: NCT03043547
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: leucovorin (400 mg/m2 as 0.5 hour infusion)
Study: NCT02015754
Drug: DEBIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in DC Beads and injected in the tumor.
Study: NCT01434108
Drug: Ornithine-phenylacetate
Normalized name: phenylacetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase A: Open-label scalating dose of OP. Treatment will be initiated at 1/3 of the final dose and will be scalated every 12 hours up to the full dose, except if there are problems of tolerance. Duration of the infusion 5 days.~Phase B: Comparative study of experimental drug vs placebo for 5 days OP (OCR-002) at a dose of 10 g diluted in 150 ml of water for injection administered as a continuous i.v. infusion for 24 hours (8.3 ml/h)during 5 days.
Study: NCT02933775
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m\^2/day×2 days
Study: NCT01546805
Drug: Zinc Supplement
Normalized name: Zinc supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: The interventional group will be requested to take zinc supplements (50mg), once daily starting 5 days prior to Botox injections and to be continued for 5 days after injection.
Study: NCT00650000
Drug: Provigil® Tablets 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg, single dose fasting
Study: NCT04084483
Drug: K-161
Normalized name: K
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-161 alternate dosage
Study: NCT01802697
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01362998
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: An infusion of epidural fentanyl started during the Cesarean section. It will be given on a patient controlled analgesia basis, with a basal rate of 60 micrograms, a demand dose of 16 micrograms, and a lockout of 15 mins.
Study: NCT00097747
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04227886
Drug: Capecitabine-Irinotecan Combination
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The concurrent chemotherapy consists of capecitabine 625 mg/m2 twice daily 5 days per week and combined with weekly irinotecan. The irinotecan dose was used based on UGT1A1 genotype of 80mg/m2 for UGT1A1\*1\*1 or 65mg/m2 for UGT1A1\*1\*28 weekly, followed by a cycle of XELIRI.
Study: NCT01697579
Drug: 5-hydroxytryptamine 3 antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV according to local labeling and/or local standard of care
Study: NCT00761852
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tab po QD for 2 weeks
Study: NCT00718549
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administred at a dose of 250 mg/m\^2/day as IV infusion over 15-30 minutes on Days 2-4 of each 28-day cycle during induction phase.
Study: NCT02493504
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100units/kg of heparin were administered for the case group after dissection prior to anastomosis.
Study: NCT03747978
Drug: Perindopril-indapamide
Normalized name: indapamide / perindopril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 5mg and Indapamide 1.25mg
Study: NCT03130179
Drug: Nicorette Strongmint lozenge 4 mg
Normalized name: Nicorette Lozenge Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of one Nicorette lozenge 4mg lozenge administrated orally to slowly dissolve in the mouth.
Study: NCT01253408
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will match study drug; taken orally with water twice per day for two days.
Study: NCT03851991
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: controle
Study: NCT00731055
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of placebo
Study: NCT03247556
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered once daily
Study: NCT03247556
Drug: 400mg SPN-812
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg SPN-812 was administered once daily and compared to Placebo
Study: NCT03247556
Drug: 600mg SPN-812
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg SPN-812 was administered once daily and compared to Placebo
Study: NCT00388180
Drug: GW501516
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00388180
Drug: GW590735
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03931876
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending dose administration
Study: NCT01179048
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximum dose of 1.8 mg placebo, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
Study: NCT01900730
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient takes placebo capsule 3 times a day by mouth for 10 weeks.
Study: NCT02107170
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01471808
Drug: CSII
Normalized name: Continuous Subcutaneous Insulin Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous subcutaneous insulin infusion for 2\~4 weeks
Study: NCT01617668
Drug: LCL161
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCL161 was available as 300 mg, tablets, which was supplied in child-resistant bottles.
Study: NCT03401112
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of placebo once daily with or without HU.
Study: NCT03334617
Drug: AZD9150
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9150 given IV at 200mg every other day of a 1-week lead-in period followed by QW
Study: NCT03334617
Drug: AZD6738
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6738 given orally at 240mg twice daily in Cycle 0 Days 1-7, followed by 7 days on treatment in each cycle between Days 22-28
Study: NCT01044498
Drug: Ortho-Novum® 1/35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each Ortho-Novum® 1/35 tablet contained 1 mg of norethindrone and 0.035 mg of ethinyl estradiol.
Study: NCT01415778
Drug: ICI176,334-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will receive single dose of ICI176,334-1
Study: NCT03633526
Drug: VX-659/TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: VX-659/TEZ/IVA FDC tablet.
Study: NCT01457053
Drug: Loop diuretics (furosemide, torsemide, bumetanide)
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with ADHF and hypervolemia will be enrolled in a prospective, randomized fashion.~Subjects will be randomized with a computer generated random number function to either ultrafiltration or diuretic therapy within 24 hours of hospitalization for the management of fluid overload.~Patients randomized to diuretic therapy will be treated with intravenous loop diuretics (e.g. furosemide, bumetanide, torsemide). The selection of diuretic, dose and frequency of diuretic administration will be determined by the treating physicians based upon clinical assessment of volume status, response to medication, and perceived safety.
Study: NCT00113230
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 900 mg/m\^2 by mouth twice a day during days of radiation for all five weeks of therapy.
Study: NCT00654017
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator to be given per protocol.
Study: NCT00003165
Drug: doxorubicin-HPMA conjugate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00667875
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03799731
Drug: Trifluridine/Tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lonsurf 35 mg/m² twice daily during 10 days per cycle
Study: NCT00227292
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 10mg per day for the first week, then 20mg per day till the end of study.
Study: NCT02429726
Drug: rAdp53
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant adenoviral p53 human gene will be administered by intra chest cavity infusion
Study: NCT00005798
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be given at a dose of 2000 mg/m2 in NS IV over one hour daily on days -6, -5, and -4. (Total dose 6000 mg/m2)
Study: NCT02224313
Drug: oral estradiol 1.0 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet of oral estradiol 1.0 mg once a day for 28 days
Study: NCT03334617
Drug: AZD6738 (ceralasertib) (240 mg or 160 mg)
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6738 given orally at 240mg or 160mg twice daily in Cycle 0 Days 1-7, followed by 7 days on treatment in each cycle between Days 22-28
Study: NCT04862533
Drug: Beta-Alanine
Normalized name: beta-alanine
DrugBank: beta-Alanine (DB03107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 1150mg of beta-alanine three times a day
Study: NCT04862533
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo three times a day
Study: NCT02654912
Drug: Reactive Focal Drug Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is the experimental arm and is described by a reactive response to passively detected index case of malaria. The reactive response consists of treating all individuals within a defined radius of each RDT-confirmed incident malaria case with dihydroartemisinin-piperaquine (DHAP).
Study: NCT02958709
Drug: High-dose: RIF, INH, PZA, EMB
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-dose rifampicin plus standard dose H,Z,E, given for 8 weeks in treatment Arms 1 and 2
Study: NCT02958709
Drug: High dose: RIF, INH, PZA, LEVO
Approvals — FDA: no, EMA: no, PMDA: no
Description: high-dose rifampicin plus standard dose H,Z, with levofloxacin substituted for ethambutol for 8 weeks in treatment Arm 2
Study: NCT02958709
Drug: Standard of care: RIF, INH, PZA, EMB
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard doses of R,H,Z,E given for 8 weeks in treatment Arm 3, control arm.
Study: NCT00138060
Drug: 5 fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/m² in bolus in day 1 and 2400 mg/m² in 46 hours perfusion
Study: NCT02285738
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily dose of Simvastatin for 4 weeks
Study: NCT02231008
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01496742
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching RO5490258 (MetMAb) placebo iv, Day 1 of each 21-day cycle
Study: NCT01496742
Drug: RO5490258
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg iv, Day 1 of each 21-day cycle
Study: NCT01062256
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo tablet administered orally as a single dose
Study: NCT04206020
Drug: SkQ1 Vehicle Solution
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: SkQ1 Ophthalmic Solution Vehicle
Study: NCT04206020
Drug: SkQ1 Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: SkQ1 Ophthalmic Solution
Study: NCT02137265
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One pill every other day
Study: NCT00137397
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02620280
Drug: MPDL3280A
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPDL3280A, 1200 mg. will be given i.v. infusion on day 1 q 3 weeks for a total of 8 cycles
Study: NCT02620280
Drug: Anthra
Normalized name: Anthralin
DrugBank: Anthralin (DB11157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC or EC (adriamycin or epirubicin and cyclophosphamide) or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles to be delivered after surgery
Study: NCT04124484
Drug: DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One DBPR108 tablet(50mg) administered orally once a day + Two Placebos matching DBPR108 tablet(100mg) administered orally once a day for 12 weeks
Study: NCT04124484
Drug: DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks
Study: NCT04124484
Drug: DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two DBPR108 tablets(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks
Study: NCT04124484
Drug: Placebo matching DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two Placebos matching DBPR108 tablet(100mg) administered orally once a day + One Placebo matching DBPR108 tablet(50mg) administered orally once a day for 12 weeks
Study: NCT02221765
Drug: PP1420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of PP 1420, administered subcutaneously. Dose levels: 8, 16, 32, 64 mg.
Study: NCT02221765
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% (w/v) saline single-dose, administered subcutaneously
Study: NCT03258242
Drug: Keluo Xin capsule
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: four capsules at a time, three times a day, taken orally and consecutively for 24 weeks or 48 weeks.
Study: NCT03258242
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: four placebo capsules at a time, three times a day, taken orally and consecutively for 24 weeks or 48 weeks.
Study: NCT02355899
Drug: PD P 506 A
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD P 506 A is a dermal patch of 4 cm² in size loaded with 2 mg 5-ALA (as 5-ALA HCl) per cm².
Study: NCT00890149
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo bid
Study: NCT01127659
Drug: testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intramuscular every 2 weeks
Study: NCT01127659
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline intramuscular every 2 weeks
Study: NCT03448393
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be diluted in an appropriate solution and infused over one hour. The dose will be based on the patient s body weight, at 900 mg/m2/dose after fludarabine infusion on Day -2.
Study: NCT03957902
Drug: acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Different dosage effect over platelet COX enzymes, non- neoplastic and neoplastic colonic tissues used as biomarkers of clinical efficacy in CRC chemoprevention
Study: NCT02178722
Drug: MK-3475
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion